

Generic Name: Linezolid

Therapeutic Class or Brand Name: Zyvox

Applicable Drugs (if Therapeutic Class): N/A

GPI Code: 1623004000

Preferred: Linezolid tablets (generic), Linezolid oral suspension (generic)

Non-preferred: Zyvox tablets, Zyvox oral suspension

Date of Origin: 2/1/2013

Date Last Reviewed / Revised: 7/15/2020

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through III are met)

- I. Documented diagnosis of one of the following conditions A through E:
 - A. Clinically documented infection that is susceptible to linezolid if the patient has a severe allergy to beta lactamase inhibitors or any antibiotic that the organism is susceptible.
 - B. Clinically documented infection that is susceptible to linezolid if the patient has failed treatment with antibiotics that the organism is susceptible.
 - C. Clinically documented vancomycin-resistant *Enterococcus faecium* infection.
 - D. Clinically documented MRSA and the patient has failed or is intolerant to vancomycin if the organism is susceptible to vancomycin.
 - E. Patient will require continuation of therapy upon hospital discharge that has a documented diagnosis of one of the above and documented initial treatment with vancomycin or linezolid while in the hospital.
- II. Linezolid is prescribed by, or after consultation with, an infectious disease physician.
- III. Non-preferred products (i.e. Zyvox® tablets, Zyvox® oral suspension) require a documented clinical reason containing details as to why generic linezolid is not appropriate or is contraindicated.

EXCLUSION CRITERIA

- Patients taking any medicinal product which inhibits monoamine oxidases A or B (i.e. phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.

OTHER CRITERIA

- Usual Doses:

Infection	Pediatric Patients	Adults and Adolescents	Duration (days)
Nosocomial pneumonia	10 mg/kg every 8 hours	600 mg every 12 hours	10 to 14
Community-acquired pneumonia, including concurrent bacteremia			
Complicated skin and skin structure infections			
Vancomycin-resistant <i>Enterococcus faecium</i> infections, including concurrent bacteremia	10 mg/kg every 8 hours	600 mg every 12 hours	14 to 28
Uncomplicated skin and skin structure infections	<u>Less than 5 years old:</u> 10 mg/kg every 8 hours <u>5 to 11 years old:</u> 10 mg/kg every 12 hours	<u>Adults:</u> 400 mg every 12 hours <u>Adolescents:</u> 600 mg every 12 hours	10 to 14

QUANTITY / DAYS SUPPLY RESTRICTIONS

- The amount needed to complete one course of therapy (see Usual Doses under Other Criteria).

APPROVAL LENGTH

- Authorization:** One time for one course of therapy (see Usual Doses under Other Criteria).
- Re-Authorization:** N/A

APPENDIX

N/A

REFERENCES

-
1. Stevens, DL, et. al., Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu444.
 2. Medi-Span.
 3. Zyvox® [Package insert] New York, NY: Pfizer; May 2020. Available at: <http://labeling.pfizer.com/showlabeling.aspx?id=649>.